Nipocalimab for treating generalised myasthenia gravis in patients aged 2 to less than 18 years old

Nipocalimab is being developed as a treatment for generalised myasthenia gravis (gMG) in children. This condition, also known as juvenile myasthenia gravis in children, is a rare autoimmune disorder that causes muscle weakness and fatigue. It happens when the immune system mistakenly attacks the connection between nerves and muscles. This can affect the eyes, face, limbs, and throat, causing drooping eyelids, double vision, difficulty speaking or swallowing, and problems with movement or breathing. Symptoms can vary over time, with periods of worsening called flare-ups. Current treatments for young children are limited, and some can cause side effects. There is a need for treatments that target the underlying cause of the disease safely and effectively.